10-Q: Rezolute Inc. Reports Q3 2026 Results, Faces sunRIZE Trial Setback

Rezolute, Inc. filed its Q3 2026 Form 10-Q, detailing financial performance and operational updates, including the disappointing outcome of its Phase 3 sunRIZE trial for congenital hyperinsulinism.

Summary

• Rezolute, Inc. reported its financial results for the quarter and nine months ended March 31, 2026.
• The company incurred a net loss of $16.17 million for the three months ended March 31, 2026, and $57.1 million for the nine months ended March 31, 2026.
• Cash and cash equivalents stood at $11.2 million as of March 31, 2026, with total capital resources of $120.2 million including marketable debt securities.
• The Phase 3 sunRIZE clinical trial for congenital hyperinsulinism did not meet its primary or key secondary endpoints, announced on December 11, 2025.
• Despite the trial's outcome, the company presented data suggesting ersodetug showed pharmacologic activity and consistent glycemic improvements compared to placebo in certain endpoints.
• Rezolute met with the FDA on March 17, 2026, to discuss the sunRIZE results, and the FDA encouraged the submission of comprehensive analysis datasets for independent evaluation.
• The company is proceeding with its Phase 3 registrational study (upLIFT) for tumor hyperinsulinism, with enrollment completion and topline data anticipated in the second half of calendar 2026.
• A reduction in workforce of 29 employees occurred on December 15, 2025, following the sunRIZE trial announcement, to conserve capital.
• The company believes its current capital resources are adequate for at least 12 months, but will require additional financing for long-term liquidity needs.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the failure of the sunRIZE Phase 3 trial to meet its endpoints, which significantly impacts the company's lead program, despite ongoing efforts to present positive aspects of the data and progress in other trials.

Positives

• Preliminary observations from the ongoing open-label extension (OLE) of the sunRIZE study show continued glycemic benefit and a significant reduction in background therapies, with some patients now on ersodetug monotherapy.
• The Phase 3 upLIFT study for tumor hyperinsulinism has been streamlined with FDA agreement, removing the need for a placebo-controlled trial.
• Ersodetug has received Orphan Drug Designation, Rare Pediatric Disease Designation, PRIME designation, Innovation Passport designation, and Breakthrough Therapy Designation for congenital hyperinsulinism.
• The company has a strong cash position of $11.2 million and total capital resources of $120.2 million as of March 31, 2026, which management believes is sufficient for at least 12 months.
• The company's investment policy focuses on liquid, high-quality debt securities with short maturities to minimize risk.

Negatives

• The Phase 3 sunRIZE clinical trial for congenital hyperinsulinism did not meet its primary or key secondary endpoints.
• The company incurred a net loss of $16.17 million for the three months ended March 31, 2026, and $57.1 million for the nine months ended March 31, 2026.
• Research and development expenses decreased by 25% for the three months ended March 31, 2026, and 4% for the nine months ended March 31, 2026, largely due to reduced ersodetug program costs.
• General and administrative expenses increased by 26% for the three months ended March 31, 2026, and 68% for the nine months ended March 31, 2026, driven by compensation and business development activities.
• A workforce reduction of 29 employees occurred on December 15, 2025, impacting operating expenses.

Risks

• The FDA may not find the submitted datasets from the sunRIZE trial adequate to support a marketing application, potentially requiring additional studies and impacting operating plans and cash resources.
• Modifications to the upLIFT trial design may not effectively demonstrate drug efficacy, and the trial may not meet its endpoints.
• The company has a history of net losses and expects to incur operating losses for the foreseeable future, requiring continuous efforts to raise additional capital.
• Future milestone payments of up to $25.0 million to XOMA upon regulatory approval and up to $202.5 million in total milestone payments and royalties to XOMA and ActiveSite upon commercialization represent significant future financial obligations.
• The company's operations are subject to risks associated with clinical-stage biopharmaceutical companies, including regulatory hurdles, clinical trial failures, and potential business failure.

Future Outlook

Rezolute expects to achieve alignment with the FDA on the path forward for congenital hyperinsulinism following the sunRIZE study and complete enrollment and announce topline data for the registrational Phase 3 upLIFT study in tumor hyperinsulinism in the second half of calendar 2026. The company anticipates needing additional equity or debt financing to fund its long-term liquidity requirements.

Management Comments

• "Although statistical significance for the secondary endpoint (% time in hypoglycemia by continuous glucose monitoring [CGM]) was not achieved at the Week 24/End of Treatment evaluation window, larger and often nominally statistically significant glycemic improvements compared to placebo were consistently observed throughout the maintenance dosing phase of the study, across time and numerous pre-specified and post-hoc CGM-based endpoints."
• "While we believe the pronounced placebo/study effect confounded the results, with a particular impact on the primary endpoint of hypoglycemia events by self-monitored blood glucose (SMBG) due to accompanying measurement bias, the totality of the data further supports previous clinical evidence that ersodetug is active against hypoglycemia in patients."
• "FDA acknowledged the challenges posed by the potential impact of varied behavioral factors on clinical trials in this heterogeneous patient population, including the associated limitations of SMBG based metrics in measuring hypoglycemia in congenital HI."
• "As a next step for the program, FDA encouraged us to submit comprehensive analysis datasets and summary outcomes for the agencys independent evaluation."
• "Based on historical precedent, supportive data from the sunRIZE study (i.e., safety and drug activity), the recent liberalization of the tumor HI study and differentiation between study endpoints, and the experience that we have reported in the historical Expanded Access Program, we remain cautiously optimistic regarding the probability of success in this indication; however, there can be no assurance that FDA will not consider the sunRIZE studys failure to meet its endpoints in assessing the approvability of tumor HI."
• "We believe that our existing capital resources will be sufficient to fund our short-term liquidity requirements. However, we will need to obtain additional equity or debt financing in order to fund all of our long-term liquidity requirements."

Industry Context

StockSavvy.ai notes that Rezolute's Q3 2026 filing highlights the inherent risks in late-stage clinical development, particularly the impact of trial design and patient-reported outcomes on regulatory submissions. The company's focus on rare diseases like hyperinsulinism places it in a segment with high unmet medical needs but also significant scientific and regulatory challenges, as evidenced by the sunRIZE trial outcome.

Comparison to Industry Standards

• The failure of the sunRIZE Phase 3 trial to meet its primary endpoints is a significant setback, a common risk in the biopharmaceutical industry where a high percentage of drugs fail in late-stage development.
• The company's net loss of $57.1 million for the nine months ended March 31, 2026, is consistent with the substantial R&D investment required for biopharmaceutical companies, particularly those focused on rare diseases.
• The company's cash burn rate of approximately $51.5 million for operating activities over nine months is within the typical range for companies at this stage, but the need for future financing is a standard challenge.
• The FDA's encouragement to submit additional data for independent evaluation, while not a guarantee of approval, reflects a common pathway for companies facing complex trial results, allowing for further scientific dialogue.

Legal Proceedings

• Several law firms have initiated investigations into the Company and filed press releases seeking stockholders to engage them to file litigation against the Company for alleged securities law violations related to the Company's Phase 3 sunRIZE trial not meeting its primary and key secondary endpoints. As of the issuance date of this Report, there have been no pending or threatened lawsuits against the Company that could reasonably be expected to have a material effect on the Company's results of operations.

Related Party Transactions

• On September 15, 2020, the Company and Handok entered into an exclusive license agreement (the Handok License) for the territory of the Republic of Korea, relating to pharmaceutical products containing compounds developed by the Company, including ersodetug and the PKI Portfolio. The Handok License requires milestone payments to the Company upon approval of an NDA and for the Company to sell products to Handok at 70% of the net selling price.

Stakeholder Impact

• Shareholders: The failure of the sunRIZE trial to meet endpoints negatively impacts shareholder value and increases the need for future capital raises, potentially diluting existing shareholders.
• Employees: A reduction in workforce of 29 employees occurred due to the trial outcome and financial preservation needs.
• Patients and Families: The setback in the sunRIZE trial delays potential access to a new therapy for congenital hyperinsulinism, although the company continues to explore pathways with the FDA.
• Creditors/Lenders: The company's financial position and need for future financing may impact its ability to service debt, though no specific impact is detailed.

Next Steps

• Submit comprehensive analysis datasets and summary outcomes from the sunRIZE trial to the FDA for independent evaluation.
• Complete enrollment and announce topline data for the registrational Phase 3 upLIFT study for tumor hyperinsulinism in the second half of calendar 2026.
• Continue to engage with the FDA regarding the approvability of ersodetug for tumor hyperinsulinism, considering the sunRIZE trial outcome.
• Seek additional equity or debt financing to fund long-term liquidity requirements.

Key Dates

Recommendation

While the failure of the sunRIZE trial is a significant negative, the company is still advancing its upLIFT trial for tumor hyperinsulinism, which has a modified design. The FDA's willingness to review additional data from the sunRIZE trial offers a glimmer of hope, and the company's cash position provides a runway. However, the uncertainty surrounding regulatory approval for ersodetug and the need for future financing warrant a cautious 'hold' stance.

Keywords

Rezolute, 10-Q, Hyperinsulinism, Ersodetug, Clinical Trial, sunRIZE, upLIFT, FDA, Rare Disease, Biopharmaceutical, Financials, SEC Filing